Tigecycline

Abstract

▴ Tigecycline is the first member of a new class of broad-spectrum antibacterials, the glycylcyclines, that has been specifically developed to overcome the two major mechanisms of tetracycline resistance (ribosomal protection and efflux). ▴ In vitro, tigecycline was active against a wide range of Gram-positive and -negative aerobic and anaerobic bacteria implicated in complicated skin and skin structure infections (cSSSIs) and complicated intra-abdominal infections (cIAIs). ▴ Intravenously administered tigecycline (recommended dosage regimen 100mg initially, followed by 50mg every 12 hours for 5–14 days) has been approved by the US FDA for the treatment of cSSSIs and cIAIs. ▴ In well designed, pivotal phase III studies, tigecycline monotherapy was noninferior to combination therapy with vancomycin 1g plus aztreonam 2g every 12 hours in hospitalised adult patients with cSSSIs (two trials; pooled clinical cure rates, 86.5% vs 88.6%) or broad-spectrum therapy with imipenem/cilastatin 200–500mg/200–500mg every 6 hours in hospitalised adult patients with cIAIs (two trials; pooled clinical cure rates, 86.1% vs 86.2%). ▴ Tigecycline was generally well tolerated in phase III studies; nausea, vomiting and diarrhoea were the most frequent adverse events in patients treated with tigecycline or an active comparator (vancomycin plus aztreonam or imipenem/cilastatin).